Xencor (NASDAQ:XNCR) Price Target Cut to $32.00

Xencor (NASDAQ:XNCRFree Report) had its price objective cut by BMO Capital Markets from $34.00 to $32.00 in a report published on Friday, Benzinga reports. They currently have an outperform rating on the biopharmaceutical company’s stock.

Several other research firms have also recently weighed in on XNCR. BTIG Research lowered their target price on Xencor from $56.00 to $38.00 and set a buy rating on the stock in a research note on Tuesday, April 16th. Royal Bank of Canada lowered their price objective on shares of Xencor from $32.00 to $31.00 and set an outperform rating on the stock in a research report on Friday. Raymond James cut their target price on shares of Xencor from $58.00 to $40.00 and set a strong-buy rating for the company in a research report on Friday. Wedbush restated an outperform rating and set a $34.00 price target (down from $36.00) on shares of Xencor in a report on Thursday, June 13th. Finally, Piper Sandler reiterated a neutral rating and set a $24.00 price objective (down from $37.00) on shares of Xencor in a report on Wednesday, February 28th. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of Moderate Buy and an average price target of $35.38.

View Our Latest Report on XNCR

Xencor Trading Down 5.2 %

Xencor stock opened at $19.52 on Friday. Xencor has a 52 week low of $16.49 and a 52 week high of $26.84. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.08 and a current ratio of 7.08. The firm has a market capitalization of $1.20 billion, a price-to-earnings ratio of -8.91 and a beta of 0.82. The company has a 50 day moving average price of $21.84 and a 200 day moving average price of $21.51.

Xencor (NASDAQ:XNCRGet Free Report) last issued its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($1.11) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.28). The business had revenue of $12.80 million during the quarter, compared to analyst estimates of $23.07 million. Xencor had a negative return on equity of 20.29% and a negative net margin of 82.23%. The business’s quarterly revenue was down 32.3% on a year-over-year basis. During the same period last year, the business earned ($1.02) EPS. Research analysts forecast that Xencor will post -3.5 EPS for the current year.

Institutional Trading of Xencor

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Jacobs Levy Equity Management Inc. acquired a new position in Xencor during the first quarter valued at approximately $4,608,000. Silvercrest Asset Management Group LLC boosted its holdings in shares of Xencor by 4.6% during the 1st quarter. Silvercrest Asset Management Group LLC now owns 144,235 shares of the biopharmaceutical company’s stock worth $3,192,000 after buying an additional 6,294 shares during the period. Baker BROS. Advisors LP grew its stake in Xencor by 122.2% in the 1st quarter. Baker BROS. Advisors LP now owns 545,431 shares of the biopharmaceutical company’s stock valued at $12,070,000 after buying an additional 300,000 shares during the last quarter. Darwin Global Management Ltd. acquired a new position in Xencor in the 1st quarter valued at $24,557,000. Finally, Price T Rowe Associates Inc. MD raised its holdings in Xencor by 9.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,819,656 shares of the biopharmaceutical company’s stock worth $84,530,000 after acquiring an additional 335,881 shares during the period.

About Xencor

(Get Free Report)

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

See Also

Analyst Recommendations for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.